The last patient has now been included in the ongoing clinical study with ACD440, the lead non-opioid drug candidate in the painless platform, which is being developed against peripheral neuropathic pain.
This double-blind, placebo-controlled, randomized cross-over study, which is carried out in collaboration with LINK Medical Research in Uppsala, is aimed at evaluating the efficacy, safety and pharmacokinetics of AlzeCure’s lead drug candidate in pain, ACD440, describes the company in a press release.
Read more: AlzeCure drug candidate is based on a 2021 Nobel discovery
“With the previous positive results from the phase Ib study, we look forward to the readout of this phase II study. There is already interest in the project and with phase II data, the project can generate even greater interest for out-licensing in a segment with a very high medical need,” said Martin Jönsson, CEO of AlzeCure Pharma.
“We see an exciting potential”
The main results from the study are expected by the summer of 2023 at the latest.
”The study has developed well and the fact that we have now been able to include the last patient in the study means that we have good hopes that the study will also deliver the results according to what we previously communicated,” said Märta Segerdahl, CMO at AlzeCure. “We see an exciting potential with ACD440, where you can broaden the further development with other formulations, thereby enabling several indications.”
Photo of Martin Jönsson, CEO, and Märta Segerdahl, CMO, AlzeCure Pharma
